Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz

February 9, 2024
Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared HolzAmgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz
Share This

Jared Holz, Mizuho, joins ‘Closing Bell Overtime’ to talk Amgen’s obesity drug trial results.


 

Latest Mizuho News

Mizuho Americas wins five FCS Portfolio Awards

Mizuho Americas wins five FCS Portfolio Awards

May 20, 2026
Mizuho Head of Investment: AI is imacting every sector in the global economy

Mizuho Head of Investment: AI is imacting every sector in the global economy

June 9, 2026
Graig Suvannavejh: ASCO is one of the highlights of our year in biotech

Graig Suvannavejh: ASCO is one of the highlights of our year in biotech

May 29, 2026

Mizuho news from around the globe

back-to-top-blue